Supprelin LA® (histrelin acetate)

Medical Guideline Disclaimer

C All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Supprelin LA is a gonadotropin releasing hormone (GnRH) agonist which inhibits the secretion of gonadotropin with continuous use. It increases levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) upon initiation of treatment but decreases both with continuous drug administration.

Length of Authorization

Coverage will be provided for 12 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 50 mg implant per 12 months

I. INITIAL APPROVAL CRITERIA

Supprelin LA may be considered medically necessary if the below condition is met AND use is consistent with the medical necessity criteria that follows:

1. Central precocious puberty
   a. Diagnosis of central precocious puberty; AND
   b. Onset of secondary sexual characteristics in one of the following:
      i. Females ≤ 8 years of age
      ii. Males ≤ 9 years of age; AND
   c. Confirmation of diagnosis as defined by one of the following:
      i. Pubertal basal level of luteinizing hormone (based on laboratory reference ranges)
      ii. A pubertal luteinizing hormone response to a GnRH stimulation test
      iii. Bone age advanced one year beyond the chronological age.
Limitations/Exclusions
Supprelin LA is not considered medically necessary for when any of the following selection criteria is met:

1) Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

II. RENEWAL CRITERIA

- Patient continues to meet INITIAL APPROVAL CRITERIA.

Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central precocious puberty</td>
<td>– 50 mg implant inserted subcutaneously every 12 months</td>
</tr>
</tbody>
</table>

Applicable Procedure Codes

- J9226 Injection, histrelin acetate, 50 mg, 1 billable unit = 50 mg

Applicable NDCs

- 67979-0002-xx Supprelin LA; 50 mg Implant

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E22.8</td>
<td>Other hyperfunction of pituitary gland (central precocious puberty)</td>
</tr>
</tbody>
</table>

References